Week In Review: CANbridge Closes $43 Million E Round For Rare Disease Drugs

CANbridge Pharma completed a $43 million Series E financing that is a follow-on to its $98 million Series D round that was announced in February. Shenzhen Xbiome, which uses AI to develop microbiome products, raised "tens of million dollars."